Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 11, 2016 11:18 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Update on Clinical Data from NY-ESO SPEAR™ T-cell Synovial Sarcoma Study at the 2016 Annual Meeting of the Connective Tissue Oncology Society (CTOS)

PHILADELPHIA and OXFORD, United Kingdom, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral...
November 11, 2016 08:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Presents Preclinical Data from a New, Wholly-owned SPEAR™ T-cell and a Second Generation SPEAR T-cell at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)

PHILADELPHIA and OXFORD, United Kingdom, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the presentation...
November 10, 2016 06:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Reports Third Quarter 2016 Financial Results

– U.S. Food and Drug Administration (FDA) lifted partial clinical hold of myxoid/round cell liposarcoma (MRCLS) study of NY-ESO SPEAR™ T-cell therapy; initiation of screening expected in 4Q 2016 ––...
November 09, 2016 16:05 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma (MRCLS)

PHILADELPHIA and OXFORD, United Kingdom, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the U.S....
November 08, 2016 16:15 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Appointment of Tal Zaks to Board of Directors

PHILADELPHIA and OXFORD, United Kingdom, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the appointment...
November 08, 2016 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Present Three Posters at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)

PHILADELPHIA and OXFORD, United Kingdom, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announced that it will present...
November 07, 2016 13:45 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Report Third Quarter 2016 Financial Results on November 10, 2016

PHILADELPHIA and OXFORD, United Kingdom, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for...
October 27, 2016 16:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Board Changes

PHILADELPHIA and OXFORD, United Kingdom, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer,...
October 27, 2016 10:05 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma

PHILADELPHIA and OXFORD, United Kingdom, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...
October 18, 2016 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10

PHILADELPHIA and OXFORD, United Kingdom, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...